Quantcast
Connect with us

A drug for autism? Potential treatment for Pitt-Hopkins syndrome offers clues

Published

on

In 2019, geeks are cool, and the idea that they might be on the autism spectrum is celebrated. Nowhere is this truer than in Silicon Valley, one of the few places in America where social quirkiness and laser focus attention to detail are more often rewarded than criticized. Often lauded as an example of a success story in autism circles, renowned scientist Temple Grandin, once told a California newspaper, “Half of Silicon Valley’s got mild autism, they just avoid the labels.”

I’m not one for diagnosing entire subcultures from newspaper articles, but the recent change in discourse around autism is good because it will hopefully push society to treat people with autism with more compassion. But this might also obscure a darker truth that the challenges and struggles for affected individuals and their families are at times overwhelming.

Current approaches to help children with autism are of limited impact, but scientists are beginning to imagine that treatments will soon be based on an understanding of specific causes.

I am the director of the Lieber Institute for Brain Development and the Maltz Research Laboratories at the Johns Hopkins University School of Medicine, where scientists study how genes and the environment shape the development of the human brain. We have identified a drug that works in individual cells and rodents of one form of autism known as Pitt-Hopkins syndrome, which is caused by a specific genetic mutation. We hope to begin human trials in a year.

Pitt-Hopkins syndrome

Many individuals who meet the criteria for autism spectrum disorder (ASD) are, despite any stereotypes, not high functioning math whizzes eagerly recruited by technology companies for their unique cognitive skills. In fact, research shows that adults with ASD are more economically, educationally and socially disadvantaged than adults with other developmental or intellectual disabilities.

ADVERTISEMENT

In severe forms of ASD, such as Pitt-Hopkins syndrome, children learn to walk between 4 and 6 years old and most individuals are unable to speak. But a rare condition like Pitt-Hopkins might offer clues for treating a range of ASD and provide insight into why those “on the spectrum” are so unique.

The term autism describes a range of disorders where the brain functions differently. This is analogous to how the term cancer describes a collection of diseases characterized by out-of-control cell growth. The diagnosis of autism is typically made at around 2 to 3 years of age as children show repetitive behaviors and have trouble socializing. Until relatively recently, ASD was regarded as uncommon and thought to be caused by bad parenting, but we now know that autism is a neurodevelopmental disorder that occurs in about 1 in 59 people and is not the result of parental behavior.

The exact causes remain unknown, but some mix of environmental factors and a plethora of usually tiny genetic differences combine to alter brain development beginning in infancy. This pushes brain development onto a trajectory that is different from what we perceive to be normal.

ADVERTISEMENT

The many factors that contribute to ASD make them particularly tricky to understand. The number of variables is high, making it almost impossible to examine any single factor in isolation. For this reason, a rare condition like Pitt-Hopkins is a valuable case for autism research and the findings may yield insights into other types of ASD. Pitt-Hopkins syndrome is caused by a mutation within a gene on the 18th chromosome. Besides creating problems with walking and speech, this mutation also causes distinct facial features and sometimes makes it hard for people to breathe.

Early signs that a child may be suffering from an autism spectrum disorder.
KateDemianov/Shutterstock.com

A first specific treatment for autism?

Because the genetic cause of Pitt-Hopkins is known, we can study the mutation in the lab to better understand how it changes brain function. The name of the mutated gene is transcription factor 4 (TCF4). It is highly active during early brain development in infancy. When the gene is turned on, it increases the production of two ion channels. These proteins allow ions (specifically, sodium and potassium) to travel in and out of the cell and are found on the membrane of the brain’s neurons.

Specifically, these ion channels become overly active, modifying how nerve cells function and how they respond to signals from other neurons, and therefore how the brain works. When we tested this in rodent and cell models, we found that the Pitt-Hopkins mutation alters the function of the brain’s neurons, which are ultimately responsible for the cognitive and social abnormalities that we find in people. In these cell and animal models, nerve cells responded abnormally to being stimulated. Instead of sending back signals when stimulated, they tended to shut down.

ADVERTISEMENT

With this knowledge, a team of investigators here at the Lieber Institute began searching for a drug that could block the activity of these ion channels and effectively change the behavior of the neurons. As it turned out, several pharmaceutical companies had created drugs to target one of these ion channels, one of which we found to work in the abnormal nerve cells and animals. We are in the final stages of licensing this compound for a human trial in young adults with Pitt-Hopkins syndrome, which we hope to start in about a year.

This would then become the first treatment for autism based on understanding a specific causative mechanism.

This doesn’t fix everything of course. By altering how each nerve functions from the time of early development, Pitt-Hopkins also forever changes the brain’s architecture. But if we can fix how the neurons operate, we may rescue normal brain activity for people with this condition.

ADVERTISEMENT

To be clear, children and young adults with Pitt-Hopkins syndrome face significantly different challenges compared to, say, an individual with Asperger’s, who is socially awkward but highly functional and gainfully employed. But no matter where we look on the spectrum, in order to better understand all forms of autism we have to start uncovering the underlying biology of these conditions. It’s opening a crack in a tiny window that can help explain what is happening.The Conversation

Daniel R. Weinberger, Director of the Lieber Institute for Brain Development and Professor, Departments of Psychiatry, Neurology, Neuroscience and The Institute of Genetic Medicine, Johns Hopkins University

This article is republished from The Conversation under a Creative Commons license. Read the original article.


Report typos and corrections to: [email protected]. Send news tips to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Breaking Banner

Want to meet with the Trump Administration? Donald Trump Jr.’s hunting buddy Tommy Hicks can help

Tommy Hicks Jr. isn’t in government, but he’s a longtime pal of the president’s son. That has put him in the room when the administration talks China and 5G policy, and it lets him help others — including one friend who had $143 million riding on the outcome.

Published

on

Over the past two years, the Trump administration has been grappling with how to handle the transition to the next generation of mobile broadband technology. With spending expected to run into hundreds of billions of dollars, the administration views it as an ultra-high-stakes competition between U.S. and Chinese companies, with enormous implications both for technology and for national security. Top officials from a raft of departments have been meeting to hash out the best approach.

ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

Continue Reading

Breaking Banner

How Trump could save America

Published

on

Donald Trump keeps claiming that his accomplishments exceed those of all previous American presidents.

Earlier this year, the White House published an amazing piece, titled “The Historic Results of Donald J. Trump’s First Two Years in Office.” Trump´s staff patted itself on the back so hard it must have hurt.

You don’t have to be a psychiatrist to realize the following: First, Trump has an obsessive desire to claim himself a success story. Second, despite his massive narcissism, he is painfully aware that he is an unmitigated failure. That is what explains his irrepressible desire to aggrandize himself.

Continue Reading
 

2020 Election

Democrats are on the verge of setting a ‘time bomb’ for any candidate who can defeat Trump

Published

on

If a new president takes over the White House in January 2021, he or she may quickly find that the Democratic Party that just won control of the executive branch left a loaded gun in the hands of the Republicans, who are all too eager to use it.

That should be the takeaway from reports about the budget negotiations between the House Democrats and the Trump administration. According to Bloomberg reporter Sahil Kapur, the parties are coalescing around an agreement to raise spending by $350 billion, offset that increase somewhat with about $75 billion, and extend the debt ceiling — now set to expire in the fall — to July 31, 2021.

Continue Reading
 
 
 

Copyright © 2019 Raw Story Media, Inc. PO Box 21050, Washington, D.C. 20009 | Masthead | Privacy Policy | For corrections or concerns, please email [email protected]

close-image
Join Me. Try Raw Story Investigates for $1. Invest in Journalism. Escape Ads.
close-image